Early Clinical and Radiological Outcomes of a Novel Robotic TKA System

Early Clinical and Radiological Outcomes of a Novel Robotic TKA System

This study aimed to evaluate the early clinical and radiological outcomes of robot assisted total knee arthroplasty, and to determine the efficiency and safety of its bone resection and implant positioning of the novel robot system.

144 patients undergoing primary TKA were enrolled in this prospective, multicenter RCT conducted in 3 hospitals. The primary outcome was the rate of patients whose postoperative alignment was less than 3° deviated from the planned evaluated by full-length weight-bearing X-rays of the lower limb at 12 weeks postoperatively. Secondary outcomes will include coronal and sagittal alignment of the components, operation times, blood loss, 12-week range of motion(ROM), 12-week postoperative functional outcomes and satisfaction evaluated by the American Knee Society Score (KSS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and adverse events (AEs).

Inclusion Criteria:

• Patients aged 18-85 years (including 18 and 85), regardless of gender;
• Patients scheduled for unilateral primary total knee arthroplasty based on the clinical judgment of the study physician;
• The subject or their guardian has been informed of the study, agrees to all terms of the trial, signs an informed consent form approved by the ethics committee, and agrees to participate in the trial.

Exclusion Criteria:

• The side scheduled for surgery has significant hip joint disease, such as substantial bone defects or severe limitations in joint mobility;
• Patients with active infections around the knee joint or systemic infections;
• Discontinuity or severe functional loss of the knee extensor mechanism, painless knee joint fusion, Charcot joint, poor surgical tolerance, or other conditions that may adversely affect surgical prognosis;
• Patients with contraindications for traditional TKA surgery;
• Pregnant or breastfeeding women;
• Patients known to have excessive alcohol consumption or substance abuse; Body mass index (BMI) > 35 kg/m²;
• Patients who have participated in other clinical trials within one month prior to signing the informed consent form;
• Patients with mental or intellectual disabilities that may affect clinical outcome evaluations;
• Patients deemed unsuitable for participation in this clinical trial by the investigator.